STOCK TITAN

Harrow (NASDAQ: HROW) furnishes 2025 Investor Day presentation via 8-K filing

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Harrow, Inc. filed a current report to share materials from its Investor Day held on September 26, 2025. The company furnished an investor presentation as Exhibit 99.1, which was used at the event and in subsequent investor meetings. The information in the presentation and in this disclosure is furnished under Regulation FD and is expressly stated as not being deemed “filed” for purposes of Section 18 of the Exchange Act, nor automatically incorporated into other Securities Act or Exchange Act filings.

Positive

  • None.

Negative

  • None.
false 0001360214 0001360214 2025-09-26 2025-09-26 0001360214 HROW:CommonStock0.001ParValuePerShareMember 2025-09-26 2025-09-26 0001360214 HROW:Sec8.625SeniorNotesDue2026Member 2025-09-26 2025-09-26 0001360214 HROW:Sec11.875SeniorNotesDue2027Member 2025-09-26 2025-09-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 26, 2025

 

HARROW, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35814   45-0567010

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

1A Burton Hills Blvd., Suite 200    
Nashville, Tennessee   37215
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (615) 733-4730

 

  Not Applicable  
  (Former Name or Former Address, if Changed Since Last Report)  

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name on exchange on which registered
Common Stock, $0.001 par value per share   HROW   The Nasdaq Stock Market LLC
8.625% Senior Notes due 2026   HROWL   The Nasdaq Stock Market LLC
11.875% Senior Notes due 2027   HROWM   The Nasdaq Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Act of 1934: Emerging growth company

 

If any emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01. Regulation FD Disclosure.

 

On September 26, 2025, Harrow, Inc. (the “Company”) hosted its Investor Day. In connection with this event, the Company is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a copy of the investor presentation (the “Presentation”) that the Company used at the event and in subsequent investor meetings.

 

The information contained in this Item 7.01 and in Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits

 

(d)   Exhibits

 

99.1   Harrow, Inc. Investor Day Presentation, dated September 26, 2025.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  HARROW, INC.
   
Dated: September 26, 2025 By: /s/ Andrew R. Boll
    Andrew R. Boll
    President and Chief Financial Officer

 

 

 

FAQ

What did Harrow, Inc. (HROW) disclose in this 8-K filing?

Harrow, Inc. disclosed that it held an Investor Day on September 26, 2025 and is furnishing its Investor Day presentation as Exhibit 99.1 to the report.

What is included as Exhibit 99.1 in Harrow, Inc.’s 8-K for HROW?

Exhibit 99.1 is the Harrow, Inc. Investor Day Presentation dated September 26, 2025, which the company used at the Investor Day and in later investor meetings.

Is the Investor Day information considered “filed” for liability purposes for HROW?

No. The company states that the information in Item 7.01 and Exhibit 99.1 is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act.

Does this Harrow, Inc. 8-K include any financial statements?

The filing lists no separate financial statements under Item 9.01, but it does reference the Investor Day presentation as Exhibit 99.1 and a cover page interactive data file as Exhibit 104.

Who signed this Harrow, Inc. (HROW) 8-K report?

The report was signed on behalf of Harrow, Inc. by Andrew R. Boll, who is identified as the company’s President and Chief Financial Officer.

On which exchanges and under which symbols are Harrow, Inc. securities listed?

Harrow, Inc.’s common stock trades on The Nasdaq Stock Market LLC under symbol HROW. Its 8.625% Senior Notes due 2026 trade as HROWL, and its 11.875% Senior Notes due 2027 trade as HROWM.
Harrow Health Inc

NASDAQ:HROW

HROW Rankings

HROW Latest News

HROW Latest SEC Filings

HROW Stock Data

1.34B
31.07M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NASHVILLE